7-05-2026, 13:14

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Notified -
Globe Newswire7-05-2026, 13:14
21-01-2026, 15:30

Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO

Notified -
Globe Newswire21-01-2026, 15:30
22-09-2025, 22:02

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Notified -
Globe Newswire22-09-2025, 22:02
21-10-2024, 11:00

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
Globe Newswire21-10-2024, 11:00